Challenges in the diagnosis and management of new-onset diabetes after transplantation.
With the availability of newer and more potent immunosuppressive agents, post-transplant survival has markedly improved. However, these agents, together with the rising age of transplant recipients, have been associated with a rise in the incidence of new-onset diabetes after transplantation (NODAT). Besides the traditional risk factors for diabetes mellitus, such as age, obesity, hypertension, and family history of diabetes, additional risk factors for NODAT are identified. These include immunosuppressive therapy, hepatitis C infection, acute rejection, and deceased donor kidney transplant. In this article, we discuss the epidemiology, risk factors, pathophysiology, clinical course, and therapeutic and diagnostic challenges of this emerging disease.
Salifu
Moro O
MO
SUNY Downstate Medical Center, Department of Medicine, Renal Fellowship Program, 450 Clarkson Avenue, Box 52, Brooklyn, NY 11203, USA. moro@salifu.net
Tedla
Fasika
F
Murty
Preethi V
PV
Aytug
Serhat
S
McFarlane
Samy I
SI
D003920:Diabetes Mellitus / Q000175:diagnosis / Q000453:epidemiology / Q000209:etiology* / Q000628:therapy*; D018149:Glucose Intolerance / Q000453:epidemiology; D006801:Humans; D007166:Immunosuppressive Agents / Q000009:adverse effects; D008403:Mass Screening; D016377:Organ Transplantation / Q000009:adverse effects*; D011183:Postoperative Complications / Q000628:therapy*; D012307:Risk Factors
D007166:Immunosuppressive Agents